Quarterly report pursuant to Section 13 or 15(d)

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Consolidated Changes in Equity (Details)

v3.19.3.a.u2
Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Consolidated Changes in Equity (Details) - USD ($)
 3 Months Ended 6 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Dec. 31, 2018
Sep. 30, 2018
Dec. 31, 2019
Dec. 31, 2018
Balance (in shares)   37,934,040     37,934,040  
Balance $ 1,174,224,000 $ 1,165,589,000 $ 1,109,469,000 $ 1,079,061,000 $ 1,165,589,000 $ 1,079,061,000
Cumulative effect adjustments due to adoption of new accounting standards and other   (879,000)   594,000 (879,000) 594,000
Net earnings 119,622,000 14,398,000 17,556,000 17,403,000 134,018,000 34,958,000
Other comprehensive income (loss) 13,275,000 (8,106,000) $ (12,379,000) (1,136,000) $ 5,169,000 $ (13,515,000)
Common stock issued for exercise of options (in shares)     24,000   287,595 189,627
Common stock issued for exercise of options 18,295,000 7,855,000 $ 2,408,000 15,611,000    
Common stock issued for restricted stock awards 0 (1,926,000) 0 (2,405,000)    
Cash dividends (12,197,000) (12,169,000) 0 (12,066,000)    
Stock-based compensation expense 10,017,000 8,267,000 6,784,000 11,327,000    
Common stock issued to employee stock purchase plan   1,096,000 0 842,000    
Employee stock purchase plan expense $ 112,000 99,000 77,000 238,000    
Share repurchases     (15,404,000)      
Balance (in shares) 38,282,251       38,282,251  
Balance $ 1,323,348,000 $ 1,174,224,000 $ 1,096,425,000 $ 1,109,469,000 $ 1,323,348,000 $ 1,096,425,000
Common Stock [Member]            
Balance (in shares) 38,084,000 37,934,000 37,803,000 37,608,000 37,934,000 37,608,000
Balance $ 381,000 $ 379,000 $ 378,000 $ 376,000 $ 379,000 $ 376,000
Common stock issued for exercise of options (in shares) 195,000 94,000   166,000    
Common stock issued for exercise of options $ 2,000 $ 1,000   $ 2,000    
Common stock issued for restricted stock awards (in shares) 4,000 50,000 3,000 24,000    
Common stock issued for restricted stock awards $ 0 $ 0 $ 0 $ 0    
Common stock issued to employee stock purchase plan (in shares)   6,000 0 5,000    
Common stock issued to employee stock purchase plan   $ 0 $ 0 $ 0    
Share repurchases (in shares)     (95,000)      
Share repurchases     $ (1,000)      
Balance (in shares) 38,283,000 38,084,000 37,735,000 37,803,000 38,283,000 37,735,000
Balance $ 383,000 $ 381,000 $ 377,000 $ 378,000 $ 383,000 $ 377,000
Additional Paid-in Capital [Member]            
Balance 334,112,000 316,797,000 274,584,000 246,568,000 316,797,000 246,568,000
Common stock issued for exercise of options 18,293,000 7,854,000   15,609,000    
Common stock issued for restricted stock awards (0) (0)        
Stock-based compensation expense 10,017,000 8,267,000 6,784,000 11,327,000    
Common stock issued to employee stock purchase plan   1,096,000   842,000    
Employee stock purchase plan expense 112,000 99,000 77,000 238,000    
Balance 362,534,000 334,112,000 283,854,000 274,584,000 362,534,000 283,854,000
Retained Earnings [Member]            
Balance 931,358,000 931,934,000 905,139,000 876,931,000 931,934,000 876,931,000
Cumulative effect adjustments due to adoption of new accounting standards and other   (879,000)   25,276,000 (879,000) 25,276,000
Net earnings 119,622,000 14,398,000 17,556,000 17,403,000    
Common stock issued for restricted stock awards   (1,926,000)   (2,405,000)    
Cash dividends (12,197,000) (12,169,000) (12,086,000) (12,066,000)    
Balance 1,038,783,000 931,358,000 895,205,000 905,139,000 1,038,783,000 895,205,000
AOCI Attributable to Parent [Member]            
Balance (91,627,000) (83,521,000) (70,632,000) (44,814,000) (83,521,000) (44,814,000)
Cumulative effect adjustments due to adoption of new accounting standards and other       (24,682,000)   (24,682,000)
Other comprehensive income (loss) 13,275,000 (8,106,000) (12,379,000) (1,136,000)    
Balance $ (78,352,000) [1],[2] $ (91,627,000) $ (83,011,000) [1] $ (70,632,000) $ (78,352,000) [1],[2] $ (83,011,000) [1]
[1] The Company reclassified ($821) to interest expense and a related tax benefit tax of $192 during the six months ended December 31, 2019. The Company had deferred tax benefits of $2,640 and $1,216 included in the accumulated other comprehensive income loss as of December 31, 2019 and December 31, 2018, respectively.
[2] The gain (loss) on the interest rate swap will be reclassified into interest expense as payments on the derivative agreement are made. Approximately ($3,842) of the ($8,633) will be reclassified into earnings in the 12 months subsequent to December 31, 2019.